Resmed (RSMDF) Non-Current Debt (2011 - 2026)
Resmed's (RSMDF) quarterly Non-Current Debt came in at $399.4 million in Q2 2026, down 39.33% on a YoY basis from $658.4 million in Q2 2025, and down 1.18% quarter-over-quarter from $404.2 million in Q1 2026.
Analysis
Resmed (RSMDF) Non-Current Debt (2011 - 2026) Analysis & Trends
Resmed (RSMDF) has reported Non-Current Debt for 16 consecutive years, with $399.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Non-Current Debt fell 39.33% year-over-year to $399.4 million; the trailing twelve-month figure through Jun 2026 stood at $399.4 million (down 39.33% YoY), and the FY2026 full-year result was $399.4 million, down 39.33% from the prior year.
- Non-Current Debt retreated to $399.4 million in Q2 2026 per RSMDF's latest filing, from $404.2 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $1.8 billion in Q4 2022 and bottomed at $399.4 million in Q2 2026.
- Historically, Non-Current Debt has averaged $863.8 million across 5 years, with a median of $683.0 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Non-Current Debt jumped 168.08% in 2022, then tumbled 51.28% in 2024.
- Over 5 years, Non-Current Debt stood at $1.8 billion in 2022, then slumped by 32.05% to $1.2 billion in 2023, then sank by 45.52% to $662.9 million in 2024, then plunged by 39.06% to $403.9 million in 2025, then fell by 1.12% to $399.4 million in 2026.
- According to Business Quant data, Non-Current Debt over the past three periods registered $399.4 million, $404.2 million, and $403.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.94 Bn | 178.34 Bn | 7.27 Bn | 29.60 Bn |
| 2 | Intuitive Surgical | 124.29 Bn | 119.08 Bn | 1.96 Bn | - |
| 3 | Medtronic | 118.22 Bn | 109.40 Bn | 6.34 Bn | 25.62 Bn |
| 4 | Stryker | 104.52 Bn | 101.04 Bn | 4.50 Bn | 14.19 Bn |
| 5 | Boston Scientific | 66.33 Bn | 65.79 Bn | 3.85 Bn | 10.92 Bn |
| 6 | Edwards Lifesciences | 49.61 Bn | 45.35 Bn | 1.35 Bn | 598.70 Mn |
| 7 | Alcon | 33.94 Bn | 32.49 Bn | 1.68 Bn | -1.00 Mn |
| 8 | Dexcom | 32.18 Bn | 30.23 Bn | 830.00 Mn | - |
| 9 | Steris | 21.13 Bn | 20.65 Bn | 684.20 Mn | 1.65 Bn |
| 10 | Resmed | 3.54 Bn | 2.07 Bn | 861.22 Mn | 399.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 399.42 Mn |
| Mar 31, 2026 | 404.17 Mn |
| Dec 31, 2025 | 403.92 Mn |
| Sep 30, 2025 | 408.66 Mn |
| Jun 30, 2025 | 658.39 Mn |
| Mar 31, 2025 | 663.13 Mn |
| Dec 31, 2024 | 662.86 Mn |
| Sep 30, 2024 | 667.58 Mn |
| Jun 30, 2024 | 697.31 Mn |
| Mar 31, 2024 | 997.05 Mn |
| Dec 31, 2023 | 1.22 Bn |
| Sep 30, 2023 | 1.35 Bn |
| Jun 30, 2023 | 1.43 Bn |
| Mar 31, 2023 | 1.58 Bn |
| Dec 31, 2022 | 1.79 Bn |
| Sep 30, 2022 | 785.44 Mn |
| Jun 30, 2022 | 765.33 Mn |
| Mar 31, 2022 | 668.74 Mn |
| Dec 31, 2021 | 667.98 Mn |
| Sep 30, 2021 | 793.67 Mn |